Venus gets market authorisation from Swiss drug authority

Tags: Companies
Pharma major Venus Remedies has secured its first marketing authorisation in Switzerland from Swiss drug authority 'Swissmedic' for its oncology drug 'Gemcitabine'.

The marketing approval for Gemcitabine will help the company further strengthen its oncology portfolio and improve its presence in this space, Venus Remedies said in a statement here today.

The Panchkula-based company plans to launch the drug early next quarter and the product will be launched in Switzerland by Swiss Pharma GmbH, with which Venus has a marketing tie-up, it said.

"The launch of this product will add to the company's top line and bottom line in the coming quarters," it said.

Venus Remedies has already received more than 20 marketing approvals for Gemcitabine injection from various countries. The product is being sold in the UK, Poland and Germany.

Gemcitabine is an anti-cancer drug used for the treatment of a variety of cancerous conditions, including the cancer of the lungs, pancreas, bladder and breast.

EDITORIAL OF THE DAY

  • The ‘new-collar’ jobs will make their presence felt as AI spreads

    For second year in a row, global elite has talked about artificial intelligence (AI), which is bound to disrupt our lives in near future.

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Sandeep Bamzai

Disequilibrium: The cleansing & the yearning

As Twitter trolls went about their ugly business against Zaira ...

BK Chaturvedi

The politics of election

Elections in five states have been announced by the election ...

Rajgopal Nidamboor

Of life’s essentiality and synchrony

It is no big deal to think of psychology as ...